LICENSE AND COLLABORATION AGREEMENTS (Details) - USD ($) $ in Thousands, shares in Millions			1 Months Ended			3 Months Ended
	Jun. 28, 2019	Oct. 09, 2015	Mar. 31, 2017	Oct. 31, 2016	Apr. 30, 2014	Mar. 31, 2020	Mar. 31, 2019
License Development and Commercialization Agreement [Line Items]
Amortization of Intangible Assets						$ 51	$ 51
Impairment charge against the intangible asset						$ 668
Patents [Member]
License Development and Commercialization Agreement [Line Items]
Payment for Termination					$ 2,000
AD Pharma Agreement
License Development and Commercialization Agreement [Line Items]
Monthly license payment receivable	$ 350
Period until which monthly license payment is receivable	18 months
Schutte | AD Pharma Agreement
License Development and Commercialization Agreement [Line Items]
Percentage of common stock held	45.70%
Abuse Deterrent Pharma, LLC
License Development and Commercialization Agreement [Line Items]
Monthly license payment receivable	$ 350
Abuse Deterrent Pharma, LLC | AD Pharma Agreement
License Development and Commercialization Agreement [Line Items]
Monthly license payment receivable	$ 350
Period until which monthly license payment is receivable	18 months					5 years
Waiver of exercise price if exercise of option occurs by certain date	$ 500
MainPointe Pharmaceuticals, LLC | AD Pharma Agreement
License Development and Commercialization Agreement [Line Items]
Waiver of exercise price if exercise of option occurs by certain date	$ 500
Period from effective date for exercise of option	5 years
Schutte
License Development and Commercialization Agreement [Line Items]
Aggregate principal of promissory notes and accrued interest	$ 6,000
Debt Conversion, Converted Instrument, Warrants or Options Issued	10.0
Schutte | AD Pharma Agreement
License Development and Commercialization Agreement [Line Items]
Aggregate principal of promissory notes and accrued interest	$ 6,000
Debt Conversion, Converted Instrument, Warrants or Options Issued	10.0
Zyla
License Development and Commercialization Agreement [Line Items]
Payment for Termination					$ 2,000
Minimum Net Sales Reaching Description						one-time $12.5 million sales-based milestone payment when worldwide Oxaydo net sales reach $150 million in a calendar year.
Agreement Termination Notice Description						Zyla may terminate the Zyla Agreement for convenience on 120 days prior written notice, which termination may not occur prior to the second anniversary of Zyla's launch of Oxaydo. Termination does not affect a party's rights accrued prior thereto, but there are no stated payments in connection with termination other than payments of obligations previously accrued. For all terminations (but not expiration), the Zyla Agreement provides for the transition of development and marketing of Oxaydo from Zyla to us, including the conveyance by Zyla to us of the trademarks and all regulatory filings and approvals relating to Oxaydo, and for Zyla's supply of Oxaydo for a transition period.
Proceeds from Milestone Payment On Agreement		$ 2,500
Monthly license payment receivable		$ 5,000
Finite-Lived Intangible Asset, Useful Life					9 years 8 months 12 days
Amortization of Intangible Assets						$ 51	$ 51
Impairment charge against the intangible asset						668
Expected amortization expense for patents per quarter.						$ 6
MainPointe (Nexafed)
License Development and Commercialization Agreement [Line Items]
Monthly license payment receivable			$ 2,500
Licensing Agreement, Royalty Percentage			7.50%
License Agreement Option Products Description			In addition, MainPointe has the option to add to the MainPointe Agreement certain additional products, or Option Products, containing PSE and utilizing the Impede Technology for a fee of $500 thousand per product (for all product strengths). Such Option Products include the product candidate Loratadine with pseudoephedrine. If the territory has been expanded prior to the exercise of a product option, the option fee will be increased to $750 thousand per product. If the territory is expanded after the payment of the $500 thousand product option fee, a one-time $250 thousand fee will be due for each product. If a third party is interested in developing or licensing rights to an Option Product, MainPointe must exercise its option for that product or its option rights for such product will terminate.
MainPointe (Nexafed) | UNITED KINGDOM
License Development and Commercialization Agreement [Line Items]
Monthly license payment receivable			$ 1,000
MainPointe (Nexafed) | JAPAN
License Development and Commercialization Agreement [Line Items]
Monthly license payment receivable			500
MainPointe (Nexafed) | South Korea [Member]
License Development and Commercialization Agreement [Line Items]
Monthly license payment receivable			$ 250
Kempharm Agreement [Member]
License Development and Commercialization Agreement [Line Items]
Monthly license payment receivable				$ 3,500
Kempharm Agreement [Member] | Minimum
License Development and Commercialization Agreement [Line Items]
Additional Upfront Payment Receivable				$ 1,000